FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to cardiology, angiology, cardiac surgery, rehabilitation, and can be used to predict adverse cardiovascular events for 12 months in patients with chronic heart failure with recurrence angina after myocardial revascularization. In the blood serum, after the end of the 6-minute walk test, the content of soluble ST2 is determined. If sST2 levels of 34.58 ng/ml and more are detected, a high risk of adverse cardiovascular events is predicted.
EFFECT: method provides an increase in the efficiency of prediction of adverse cardiovascular events due to the selection of a group of patients with chronic heart failure with an intermediate and reduced left ventricular ejection fraction with recurrence of angina after myocardial revascularization.
1 cl, 1 dwg, 1 tbl, 2 ex
